Skip to main content
NCBI home page
Protein & Cell logoLink to Protein & Cell
. 2010 Feb 6;1(2):124–132. doi: 10.1007/s13238-010-0016-z

Molecular and cellular bases of chronic myeloid leukemia

Yaoyu Chen 1, Cong Peng 1, Dongguang Li 2, Shaoguang Li 1,✉
PMCID: PMC4875160  PMID: 21203982

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the overproduction of granulocytes, which leads to high white blood cell counts and splenomegaly in patients. Based on clinical symptoms and laboratory findings, CML is classified into three clinical phases, often starting with a chronic phase, progressing to an accelerated phase and ultimately ending in a terminal phase called blast crisis. Blast crisis phase of CML is clinically similar to an acute leukemia; in particular, B-cell acute lymphoblastic leukemia (B-ALL) is a severe form of acute leukemia in blast crisis, and there is no effective therapy for it yet. CML is induced by the BCR-ABL oncogene, whose gene product is a BCR-ABL tyrosine kinase. Currently, inhibition of BCR-ABL kinase activity by its kinase inhibitor such as imatinib mesylate (Gleevec) is a major therapeutic strategy for CML. However, the inability of BCR-ABL kinase inhibitors to completely kill leukemia stem cells (LSCs) indicates that these kinase inhibitors are unlikely to cure CML. In addition, drug resistance due to the development of BCRABL mutations occurs before and during treatment of CML with kinase inhibitors. A critical issue to resolve this problem is to fully understand the biology of LSCs, and to identify key genes that play significant roles in survival and self-renewal of LSCs. In this review, we will focus on LSCs in CML by summarizing and discussing available experimental results, including the original studies from our own laboratory.

Keywords: BCR-ABL, leukemic stem cells, CML, therapeutic agents

References

  1. Ahuja H.G., Jat P.S., Foti A., Bar-Eli M., Cline M.J. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood. 1991;78:3259–3268. [PubMed] [Google Scholar]
  2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988. doi: 10.1073/pnas.0530291100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartram C.R., de Klein A., Hagemeijer A., van Agthoven T., Geurts van Kessel A., Bootsma D., Grosveld G., Ferguson-Smith M.A., Davies T., Stone M., et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277–280. doi: 10.1038/306277a0. [DOI] [PubMed] [Google Scholar]
  4. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., Witte O.N., Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212–214. doi: 10.1126/science.3460176. [DOI] [PubMed] [Google Scholar]
  5. Bhatia R., Holtz M., Niu N., Gray R., Snyder D.S., Sawyers C.L., Arber D.A., Slovak M.L., Forman S.J. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701–4707. doi: 10.1182/blood-2002-09-2780. [DOI] [PubMed] [Google Scholar]
  6. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737. doi: 10.1038/nm0797-730. [DOI] [PubMed] [Google Scholar]
  7. Bruns I., Czibere A., Fischer J.C., Roels F., Cadeddu R.P., Buest S., Bruennert D., Huenerlituerkoglu A.N., Stoecklein N.H., Singh R., et al. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia. 2009;23:892–899. doi: 10.1038/leu.2008.392. [DOI] [PubMed] [Google Scholar]
  8. Canaani E., Gale R.P., Steiner-Saltz D., Berrebi A., Aghai E., Januszewicz E. Altered transcription of an oncogene in chronic myeloid leukaemia. Lancet. 1984;1:593–595. doi: 10.1016/S0140-6736(84)90997-8. [DOI] [PubMed] [Google Scholar]
  9. Catalano A., Rodilossi S., Caprari P., Coppola V., Procopio A. 5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation. EMBO J. 2005;24:170–179. doi: 10.1038/sj.emboj.7600502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chen, Y., Hu, Y., Michaels, S., Segal, D., Brown, D., and Li, S. (2009a). Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia. In Press. [DOI] [PMC free article] [PubMed]
  11. Chen Y., Hu Y., Zhang H., Peng C., Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009;41:783–792. doi: 10.1038/ng.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dai Z., Kerzic P., Schroeder W.G., McNiece I.K. Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis. J Biol Chem. 2001;276:28954–28960. doi: 10.1074/jbc.M101170200. [DOI] [PubMed] [Google Scholar]
  13. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., et al. Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037. doi: 10.1056/NEJM200104053441401. [DOI] [PubMed] [Google Scholar]
  14. Fainstein E., Marcelle C., Rosner A., Canaani E., Gale R.P., Dreazen O., Smith S.D., Croce C.M. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature. 1987;330:386–388. doi: 10.1038/330386a0. [DOI] [PubMed] [Google Scholar]
  15. Feinstein E., Cimino G., Gale R.P., Alimena G., Berthier R., Kishi K., Goldman J., Zaccaria A., Berrebi A., Canaani E. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci U S A. 1991;88:6293–6297. doi: 10.1073/pnas.88.14.6293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fialkow P.J., Gartler S.M., Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci U S A. 1967;58:1468–1471. doi: 10.1073/pnas.58.4.1468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63:125–130. doi: 10.1016/0002-9343(77)90124-3. [DOI] [PubMed] [Google Scholar]
  18. Ghaffari S., Daley G.Q., Lodish H.F. Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia. 1999;13:1200–1206. doi: 10.1038/sj.leu.2401467. [DOI] [PubMed] [Google Scholar]
  19. Goga A., McLaughlin J., Afar D.E., Saffran D.C., Witte O.N. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 1995;82:981–988. doi: 10.1016/0092-8674(95)90277-5. [DOI] [PubMed] [Google Scholar]
  20. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–325. doi: 10.1182/blood.V99.1.319. [DOI] [PubMed] [Google Scholar]
  21. Groffen J., Heisterkamp N., Stephenson J.R., van Kessel A.G., de Klein A., Grosveld G., Bootsma D. c-sis is translocated from chromosome 22 to chromosome 9 in chronic myelocytic leukemia. J Exp Med. 1983;158:9–15. doi: 10.1084/jem.158.1.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93–99. doi: 10.1016/0092-8674(84)90077-1. [DOI] [PubMed] [Google Scholar]
  23. Gross A.W., Ren R. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells. Oncogene. 2000;19:6286–6296. doi: 10.1038/sj.onc.1204023. [DOI] [PubMed] [Google Scholar]
  24. Gross A.W., Zhang X., Ren R. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol. 1999;19:6918–6928. doi: 10.1128/MCB.19.10.6918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Heisterkamp N., Groffen J., Stephenson J.R., Spurr N.K., Goodfellow P.N., Solomon E., Carritt B., Bodmer W.F. Chromosomal localization of human cellular homologues of two viral oncogenes. Nature. 1982;299:747–749. doi: 10.1038/299747a0. [DOI] [PubMed] [Google Scholar]
  26. Hernandez S.E., Krishnaswami M., Miller A.L., Koleske A.J. How do Abl family kinases regulate cell shape and movement? Trends Cell Biol. 2004;14:36–44. doi: 10.1016/j.tcb.2003.11.003. [DOI] [PubMed] [Google Scholar]
  27. Hu Y., Chen Y., Douglas L., Li S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 2009;23:109–116. doi: 10.1038/leu.2008.262. [DOI] [PubMed] [Google Scholar]
  28. Hu Y., Swerdlow S., Duffy T.M., Weinmann R., Lee F.Y., Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in mice. Proc Natl Acad Sci U S A. 2006;103:16870–16875. doi: 10.1073/pnas.0606509103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Jennings B.A., Mills K.I. c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leuk Res. 1998;22:899–903. doi: 10.1016/S0145-2126(98)00097-6. [DOI] [PubMed] [Google Scholar]
  30. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–1261. doi: 10.1056/NEJMra061808. [DOI] [PubMed] [Google Scholar]
  31. Knapp H.R. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med. 1990;323:1745–1748. doi: 10.1056/NEJM199012203232506. [DOI] [PubMed] [Google Scholar]
  32. Lessard J., Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003;423:255–260. doi: 10.1038/nature01572. [DOI] [PubMed] [Google Scholar]
  33. Li S., Couvillon A.D., Brasher B.B., Van Etten R.A. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. EMBO J. 2001;20:6793–6804. doi: 10.1093/emboj/20.23.6793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Li S., Ilaria R.L., Jr., Million R.P., Daley G.Q., Van Etten R.A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399–1412. doi: 10.1084/jem.189.9.1399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375–13378. doi: 10.1074/jbc.273.22.13375. [DOI] [PubMed] [Google Scholar]
  36. McWhirter J.R., Galasso D.L., Wang J.Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13:7587–7595. doi: 10.1128/MCB.13.12.7587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Melo J.V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–2384. [PubMed] [Google Scholar]
  38. Million R.P., Van Etten R.A. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood. 2000;96:664–670. [PubMed] [Google Scholar]
  39. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma. 1993;11(Suppl1):11–15. doi: 10.3109/10428199309047856. [DOI] [PubMed] [Google Scholar]
  40. Mullighan C.G., Goorha S., Radtke I., Miller C.B., Coustan-Smith E., Dalton J.D., Girtman K., Mathew S., Ma J., Pounds S.B., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–764. doi: 10.1038/nature05690. [DOI] [PubMed] [Google Scholar]
  41. Nieborowska-Skorska M., Hoser G., Kossev P., Wasik M.A., Skorski T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood. 2002;99:4531–4539. doi: 10.1182/blood.V99.12.4531. [DOI] [PubMed] [Google Scholar]
  42. Nowell P.C., Hungerford D.A. Chromosome studies in human leukemia. IV. Myeloproliferative syndrome and other atypical myeloid disorders. J Natl Cancer Inst. 1962;29:911–931. [PubMed] [Google Scholar]
  43. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895–902. doi: 10.1038/nrc1232. [DOI] [PubMed] [Google Scholar]
  44. Park C.Y., Tseng D., Weissman I.L. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther. 2009;17:219–230. doi: 10.1038/mt.2008.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Pendergast A.M., Gishizky M.L., Havlik M.H., Witte O.N. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol. 1993;13:1728–1736. doi: 10.1128/MCB.13.3.1728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Prokocimer M., Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood. 1994;84:2391–2411. [PubMed] [Google Scholar]
  47. Prywes R., Foulkes J.G., Rosenberg N., Baltimore D. Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation. Cell. 1983;34:569–579. doi: 10.1016/0092-8674(83)90389-6. [DOI] [PubMed] [Google Scholar]
  48. Puil L., Liu J., Gish G., Mbamalu G., Bowtell D., Pelicci P.G., Arlinghaus R., Pawson T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764–773. doi: 10.1002/j.1460-2075.1994.tb06319.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Rameh L.E., Cantley L.C. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem. 1999;274:8347–8350. doi: 10.1074/jbc.274.13.8347. [DOI] [PubMed] [Google Scholar]
  50. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172–183. doi: 10.1038/nrc1567. [DOI] [PubMed] [Google Scholar]
  51. Reya T., Duncan A.W., Ailles L., Domen J., Scherer D.C., Willert K., Hintz L., Nusse R., Weissman I.L. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409–414. doi: 10.1038/nature01593. [DOI] [PubMed] [Google Scholar]
  52. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111. doi: 10.1038/35102167. [DOI] [PubMed] [Google Scholar]
  53. Rossi D.J., Jamieson C.H., Weissman I.L. Stems cells and the pathways to aging and cancer. Cell. 2008;132:681–696. doi: 10.1016/j.cell.2008.01.036. [DOI] [PubMed] [Google Scholar]
  54. Rowley J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293. doi: 10.1038/243290a0. [DOI] [PubMed] [Google Scholar]
  55. Saglio G., Guerrasio A., Rosso C., Zaccaria A., Tassinari A., Serra A., Rege-Cambrin G., Mazza U., Gavosto F. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1990;76:1819–1824. [PubMed] [Google Scholar]
  56. Sattler M., Mohi M.G., Pride Y.B., Quinnan L.R., Malouf N.A., Podar K., Gesbert F., Iwasaki H., Li S., Van Etten R.A., et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002;1:479–492. doi: 10.1016/S1535-6108(02)00074-0. [DOI] [PubMed] [Google Scholar]
  57. Schwartzberg P.L., Stall A.M., Hardin J.D., Bowdish K.S., Humaran T., Boast S., Harbison M.L., Robertson E.J., Goff S.P. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell. 1991;65:1165–1175. doi: 10.1016/0092-8674(91)90012-N. [DOI] [PubMed] [Google Scholar]
  58. Shtivelman E., Lifshitz B., Gale R.P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550–554. doi: 10.1038/315550a0. [DOI] [PubMed] [Google Scholar]
  59. Sill H., Goldman J.M., Cross N.C. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 1995;85:2013–2016. [PubMed] [Google Scholar]
  60. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–5828. [PubMed] [Google Scholar]
  61. Smith K.M., Yacobi R., Van Etten R.A. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell. 2003;12:27–37. doi: 10.1016/S1097-2765(03)00274-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Stam K., Heisterkamp N., Reynolds F.H., Jr., Groffen J. Evidence that the phl gene encodes a 160,000-dalton phosphor-protein with associated kinase activity. Mol Cell Biol. 1987;7:1955–1960. doi: 10.1128/MCB.7.5.1955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39. doi: 10.1016/S0092-8674(00)81780-8. [DOI] [PubMed] [Google Scholar]
  64. Taipale J., Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001;411:349–354. doi: 10.1038/35077219. [DOI] [PubMed] [Google Scholar]
  65. Takahashi N., Miura I., Saitoh K., Miura A.B. Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood. 1998;92:4758–4763. [PubMed] [Google Scholar]
  66. Tybulewicz V.L., Crawford C.E., Jackson P.K., Bronson R.T., Mulligan R.C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991;65:1153–1163. doi: 10.1016/0092-8674(91)90011-M. [DOI] [PubMed] [Google Scholar]
  67. Varnai P., Bondeva T., Tamas P., Toth B., Buday L., Hunyady L., Balla T. Selective cellular effects of overexpressed pleckstrin-homology domains that recognize PtdIns(3,4,5)P3 suggest their interaction with protein binding partners. J Cell Sci. 2005;118:4879–4888. doi: 10.1242/jcs.02606. [DOI] [PubMed] [Google Scholar]
  68. Voncken J.W., van Schaick H., Kaartinen V., Deemer K., Coates T., Landing B., Pattengale P., Dorseuil O., Bokoch G.M., Groffen J., et al. Increased neutrophil respiratory burst in bcr-null mutants. Cell. 1995;80:719–728. doi: 10.1016/0092-8674(95)90350-X. [DOI] [PubMed] [Google Scholar]
  69. Wang J.C., Dick J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15:494–501. doi: 10.1016/j.tcb.2005.07.004. [DOI] [PubMed] [Google Scholar]
  70. Wertheim J.A., Perera S.A., Hammer D.A., Ren R., Boettiger D., Pear W.S. Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood. 2003;102:2220–2228. doi: 10.1182/blood-2003-01-0062. [DOI] [PubMed] [Google Scholar]
  71. Westbrook C.A., Hooberman A.L., Spino C., Dodge R.K., Larson R.A., Davey F., Wurster-Hill D.H., Sobol R.E., Schiffer C., Bloomfield C.D. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762) Blood. 1992;80:2983–2990. [PubMed] [Google Scholar]
  72. Wong S., Witte O.N. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004;22:247–306. doi: 10.1146/annurev.immunol.22.012703.104753. [DOI] [PubMed] [Google Scholar]
  73. Woodring P.J., Hunter T., Wang J.Y. Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci. 2003;116:2613–2626. doi: 10.1242/jcs.00622. [DOI] [PubMed] [Google Scholar]
  74. Wymann M.P., Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol. 2008;9:162–176. doi: 10.1038/nrm2335. [DOI] [PubMed] [Google Scholar]
  75. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., Haug J.S., Rupp D., Porter-Westpfahl K.S., Wiedemann L.M., et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 2006;441:518–522. doi: 10.1038/nature04747. [DOI] [PubMed] [Google Scholar]
  76. Zhang X., Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998;92:3829–3840. [PubMed] [Google Scholar]
  77. Zhang X., Subrahmanyam R., Wong R., Gross A.W., Ren R. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol Cell Biol. 2001;21:840–853. doi: 10.1128/MCB.21.3.840-853.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Zhao C., Blum J., Chen A., Kwon H.Y., Jung S.H., Cook J.M., Lagoo A., Reya T. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12:528–541. doi: 10.1016/j.ccr.2007.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., Kwon H.Y., Kim J., Chute J.P., Rizzieri D., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458:776–779. doi: 10.1038/nature07737. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES